Xenon Pharmaceuticals Inc. Q2 FY2025 earnings call

Key Points

• Advancement in the pipeline with significant progress in azetukalner's Phase III clinical trial X-TOLE2, which completed patient recruitment and is on track for top line results in early 2026.
• Initiation of new studies: X-NOVA3 in major depressive disorder (MDD) and X-CEED in bipolar depression 1 and 2.
• Early-stage pipeline with multiple regulatory filings expected for first-in-human trials across ion channel targets.
• Introduction of Darren Cline as Chief Commercial Officer, bringing experience in epilepsy commercialization.

No specific financial performance data for product segments in terms of absolute revenue and contribution % provided in the transcript.

Forward-Looking Statements

• Anticipation of top line results from X-TOLE2 in early 2026.
• Expectation of sufficient cash to fund operations into 2027.
• Initiation of Phase III studies in MDD and bipolar depression.

Risks Identified

• Potential safety issues with new molecules, such as cardiovascular signals with earlier Nav1.7 molecules and liver toxicity concerns with some Kv7 compounds.
• Challenges in commercialization, including overcoming inertia in the epilepsy community and competition.

Q: Remind on timing for filing after X-TOLE2 FOS data and confidence on Nav1.7 safety A: Ian Mortimer said ~6 months from top line to NDA filing and confident in Nav1.7 safety based on preclinical data.

Q: X-TOLE2 patient randomization, recruitment split, sites A: Ian and Chris mentioned recent completion of recruitment, baseline period, and ongoing details on sites and recruitment.

Q: X-TOLE2 study size, delta, dropout rate A: Ian and Chris discussed study design, powering, and expectation of statistical significance.

Q: Nav1.7 molecule profile, PK, dosing, pain model A: Ian Mortimer talked about PK being determined in clinical trials, consideration of IV formulation, and proof-of-concept study design.

Q: X-TOLE2 blinded demographics, bipolar study site overlap, pain study efficacy parameters A: Ian and Chris discussed similar demographics to X-TOLE, potential site overlap in bipolar and MDD, and plans for assessing efficacy in pain studies.

Q: Bipolar depression study interim analysis, efficacy separation A: Ian and Chris mentioned interim analysis based on recruitment, aiming for statistical significance.

Q: Competitive front, Biohaven's MDD readout, epilepsy market headwinds A: Ian and Darren discussed mechanism support in MDD and excitement about epilepsy market launch.

Q: Bipolar depression Type 1 vs Type 2, mania as secondary endpoint A: Chris Kenney explained stratification and monitoring mania as a safety endpoint.

Q: Kv7 for pain liver toxicity, quality of life, X-TOLE2 top line details A: Ian and Chris discussed liver toxicity monitoring, quality of life data, and top line release details.

Q: Kv7 for pain dose response, Nav1.7 combination A: Ian and Chris talked about dose response expectation and consideration of combinations in Nav1.7 program.